Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiomyolipoma | 1 | 2022 | 4 | 0.720 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2022 | 13 | 0.720 |
Why?
|
| Hypotension | 1 | 2022 | 187 | 0.640 |
Why?
|
| Lung Neoplasms | 8 | 2021 | 1545 | 0.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2020 | 357 | 0.570 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2021 | 144 | 0.560 |
Why?
|
| Chemoradiotherapy | 7 | 2020 | 125 | 0.550 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 421 | 0.530 |
Why?
|
| Immunotherapy | 4 | 2020 | 768 | 0.410 |
Why?
|
| Radiosurgery | 3 | 2020 | 148 | 0.400 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 127 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1459 | 0.350 |
Why?
|
| Catheter Ablation | 2 | 2026 | 324 | 0.320 |
Why?
|
| Tumor Escape | 2 | 2020 | 65 | 0.290 |
Why?
|
| Heart Failure | 1 | 2022 | 2332 | 0.290 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2019 | 23 | 0.280 |
Why?
|
| Piperidines | 2 | 2020 | 223 | 0.270 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2019 | 57 | 0.270 |
Why?
|
| Tumor Microenvironment | 7 | 2021 | 713 | 0.270 |
Why?
|
| Neoplasms | 5 | 2020 | 3016 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1336 | 0.270 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2019 | 101 | 0.260 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2026 | 161 | 0.200 |
Why?
|
| Patient Readmission | 3 | 2022 | 442 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 388 | 0.200 |
Why?
|
| Frozen Sections | 1 | 2022 | 27 | 0.190 |
Why?
|
| Pathology, Surgical | 1 | 2022 | 17 | 0.190 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2021 | 11 | 0.180 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 3748 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 821 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 26 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 8 | 0.160 |
Why?
|
| Oxadiazoles | 1 | 2020 | 26 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2021 | 146 | 0.150 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 235 | 0.150 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2019 | 12 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2019 | 16 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 236 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 65 | 0.150 |
Why?
|
| Immunity | 1 | 2020 | 178 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2022 | 541 | 0.150 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2019 | 7 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 257 | 0.150 |
Why?
|
| Survival Rate | 5 | 2026 | 2114 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 136 | 0.140 |
Why?
|
| Oximes | 1 | 2019 | 56 | 0.140 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2018 | 3 | 0.140 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 61 | 0.140 |
Why?
|
| Receptors, OX40 | 1 | 2018 | 9 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2026 | 738 | 0.140 |
Why?
|
| Immune Tolerance | 1 | 2019 | 151 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 310 | 0.130 |
Why?
|
| Proton Therapy | 1 | 2019 | 155 | 0.130 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2021 | 279 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 236 | 0.130 |
Why?
|
| Aged | 8 | 2026 | 21025 | 0.130 |
Why?
|
| Mice | 11 | 2021 | 18301 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2019 | 296 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2020 | 446 | 0.120 |
Why?
|
| Humans | 21 | 2026 | 131163 | 0.120 |
Why?
|
| Female | 16 | 2026 | 70963 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 37 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2019 | 697 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1089 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2020 | 804 | 0.110 |
Why?
|
| Kidney | 1 | 2022 | 1282 | 0.110 |
Why?
|
| Mitochondria | 1 | 2020 | 785 | 0.110 |
Why?
|
| Registries | 1 | 2021 | 1634 | 0.110 |
Why?
|
| Incidence | 1 | 2022 | 3360 | 0.100 |
Why?
|
| Animals | 12 | 2021 | 33912 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2065 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 981 | 0.100 |
Why?
|
| Hypertension | 1 | 2021 | 1356 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 5196 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1826 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 750 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1272 | 0.080 |
Why?
|
| Coronary Angiography | 2 | 2023 | 450 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2026 | 17753 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 972 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 114 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2019 | 62 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12936 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 155 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4697 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 463 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6797 | 0.070 |
Why?
|
| Radiotherapy Dosage | 2 | 2019 | 216 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1064 | 0.060 |
Why?
|
| Middle Aged | 6 | 2026 | 28601 | 0.060 |
Why?
|
| Male | 9 | 2026 | 64957 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1216 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2019 | 1483 | 0.060 |
Why?
|
| Propensity Score | 1 | 2026 | 271 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1287 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2020 | 6459 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2022 | 63 | 0.050 |
Why?
|
| Adult | 5 | 2023 | 31282 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 2026 | 0.040 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 7 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2020 | 9 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 49 | 0.040 |
Why?
|
| Smad1 Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| Follistatin | 1 | 2020 | 37 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 96 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 4738 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 20 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 323 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 68 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 142 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 83 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 378 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 130 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2022 | 345 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4886 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 562 | 0.030 |
Why?
|
| Heart | 1 | 2023 | 650 | 0.030 |
Why?
|
| Kynurenine | 1 | 2018 | 24 | 0.030 |
Why?
|
| Tryptophan | 1 | 2018 | 84 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 482 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 386 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 240 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 502 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 358 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 500 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 193 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 713 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 230 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 825 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 179 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 570 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 108 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 573 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1129 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 1011 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1618 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1267 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 663 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1103 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 1211 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 960 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1722 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1939 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1801 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 2406 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 4686 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 11074 | 0.020 |
Why?
|
| United States | 1 | 2021 | 12072 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 10103 | 0.010 |
Why?
|